An observational cohort study of histological screening for BK polyomavirus nephropathy following viral replication in plasma
Copyright © 2023 International Society of Nephrology. Published by Elsevier Inc. All rights reserved..
Systematic screening for BKPyV-DNAemia has been advocated to aid prevention and treatment of polyomavirus associated nephropathy (PyVAN), an important cause of kidney graft failure. The added value of performing a biopsy at time of BKPyV-DNAemia, to distinguish presumptive PyVAN (negative SV40 immunohistochemistry) and proven PyVAN (positive SV40) has not been established. Therefore, we studied an unselected cohort of 950 transplantations, performed between 2008-2017. BKPyV-DNAemia was detected in 250 (26.3%) transplant recipients, and positive SV40 in 91 cases (9.6%). Among 209 patients with a concurrent biopsy at time of first BKPyV-DNAemia, 60 (28.7%) biopsies were SV40 positive. Plasma viral load showed high diagnostic value for concurrent SV40 positivity (ROC-AUC 0.950, 95% confidence interval 0.916-0.978) and the semiquantitatively scored percentage of tubules with evidence of polyomavirus replication (pvl score) (0.979, 0.968-0.988). SV40 positivity was highly unlikely when plasma viral load is below 4 log10 copies/ml (negative predictive value 0.989, 0.979-0.994). In SV40 positive patients, higher plasma BKPyV-DNA load and higher pvl scores were associated with slower viral clearance from the blood (hazard ratio 0.712, 95% confidence interval 0.604-0.839, and 0.327, 0.161-0.668, respectively), whereas the dichotomy positivity/negativity of SV40 immunohistochemistry did not predict viral clearance. Although the pvl score offers some prognostic value for viral clearance on top of plasma viral load, the latter provided good guidance for when a biopsy was unnecessary to exclude PyVAN. Thus, the distinction between presumptive and proven PyVAN, based on SV40 immunohistochemistry, has limited clinical value. Hence, management of BKPyV-DNAemia and immunosuppression reduction should be weighed against the risk of occurrence of rejection, or exacerbation of rejection observed concomitantly.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:104 |
|---|---|
| Enthalten in: |
Kidney international - 104(2023), 5 vom: 15. Nov., Seite 1018-1034 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cleenders, Evert [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biopsy |
|---|
| Anmerkungen: |
Date Revised 20.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.kint.2023.07.025 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360976166 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360976166 | ||
| 003 | DE-627 | ||
| 005 | 20231226084153.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.kint.2023.07.025 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1203.xml |
| 035 | |a (DE-627)NLM360976166 | ||
| 035 | |a (NLM)37598855 | ||
| 035 | |a (PII)S0085-2538(23)00563-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cleenders, Evert |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An observational cohort study of histological screening for BK polyomavirus nephropathy following viral replication in plasma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 International Society of Nephrology. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Systematic screening for BKPyV-DNAemia has been advocated to aid prevention and treatment of polyomavirus associated nephropathy (PyVAN), an important cause of kidney graft failure. The added value of performing a biopsy at time of BKPyV-DNAemia, to distinguish presumptive PyVAN (negative SV40 immunohistochemistry) and proven PyVAN (positive SV40) has not been established. Therefore, we studied an unselected cohort of 950 transplantations, performed between 2008-2017. BKPyV-DNAemia was detected in 250 (26.3%) transplant recipients, and positive SV40 in 91 cases (9.6%). Among 209 patients with a concurrent biopsy at time of first BKPyV-DNAemia, 60 (28.7%) biopsies were SV40 positive. Plasma viral load showed high diagnostic value for concurrent SV40 positivity (ROC-AUC 0.950, 95% confidence interval 0.916-0.978) and the semiquantitatively scored percentage of tubules with evidence of polyomavirus replication (pvl score) (0.979, 0.968-0.988). SV40 positivity was highly unlikely when plasma viral load is below 4 log10 copies/ml (negative predictive value 0.989, 0.979-0.994). In SV40 positive patients, higher plasma BKPyV-DNA load and higher pvl scores were associated with slower viral clearance from the blood (hazard ratio 0.712, 95% confidence interval 0.604-0.839, and 0.327, 0.161-0.668, respectively), whereas the dichotomy positivity/negativity of SV40 immunohistochemistry did not predict viral clearance. Although the pvl score offers some prognostic value for viral clearance on top of plasma viral load, the latter provided good guidance for when a biopsy was unnecessary to exclude PyVAN. Thus, the distinction between presumptive and proven PyVAN, based on SV40 immunohistochemistry, has limited clinical value. Hence, management of BKPyV-DNAemia and immunosuppression reduction should be weighed against the risk of occurrence of rejection, or exacerbation of rejection observed concomitantly | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a biopsy | |
| 650 | 4 | |a kidney transplantation | |
| 650 | 4 | |a polyomavirus nephropathy | |
| 650 | 4 | |a screening | |
| 700 | 1 | |a Koshy, Priyanka |e verfasserin |4 aut | |
| 700 | 1 | |a Van Loon, Elisabet |e verfasserin |4 aut | |
| 700 | 1 | |a Lagrou, Katrien |e verfasserin |4 aut | |
| 700 | 1 | |a Beuselinck, Kurt |e verfasserin |4 aut | |
| 700 | 1 | |a Andrei, Graciela |e verfasserin |4 aut | |
| 700 | 1 | |a Crespo, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a De Vusser, Katrien |e verfasserin |4 aut | |
| 700 | 1 | |a Kuypers, Dirk |e verfasserin |4 aut | |
| 700 | 1 | |a Lerut, Evelyne |e verfasserin |4 aut | |
| 700 | 1 | |a Mertens, Kris |e verfasserin |4 aut | |
| 700 | 1 | |a Mineeva-Sangwo, Olga |e verfasserin |4 aut | |
| 700 | 1 | |a Randhawa, Parmjeet |e verfasserin |4 aut | |
| 700 | 1 | |a Senev, Aleksandar |e verfasserin |4 aut | |
| 700 | 1 | |a Snoeck, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Sprangers, Ben |e verfasserin |4 aut | |
| 700 | 1 | |a Tinel, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Van Craenenbroeck, Amaryllis |e verfasserin |4 aut | |
| 700 | 1 | |a van den Brand, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Van Ranst, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Verbeke, Geert |e verfasserin |4 aut | |
| 700 | 1 | |a Coemans, Maarten |e verfasserin |4 aut | |
| 700 | 1 | |a Naesens, Maarten |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kidney international |d 1972 |g 104(2023), 5 vom: 15. Nov., Seite 1018-1034 |w (DE-627)NLM000007188 |x 1523-1755 |7 nnns |
| 773 | 1 | 8 | |g volume:104 |g year:2023 |g number:5 |g day:15 |g month:11 |g pages:1018-1034 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.kint.2023.07.025 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 104 |j 2023 |e 5 |b 15 |c 11 |h 1018-1034 | ||